Should I buy or sell Helius Medical Technologies stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HSDT shares. View HSDT analyst ratings or view top-rated stocks .

What is Helius Medical Technologies' stock price target for 2024?

1 brokerages have issued 12-month price targets for Helius Medical Technologies' stock. Their HSDT share price targets range from $24.00 to $85.00. On average, they anticipate the company's share price to reach $54.50 in the next year. This suggests a possible upside of 950.1% from the stock's current price. View analysts price targets for HSDT or view top-rated stocks among Wall Street analysts .

How have HSDT shares performed in 2024?

Helius Medical Technologies' stock was trading at $8.04 at the beginning of the year. Since then, HSDT shares have decreased by 35.4% and is now trading at $5.19. View the best growth stocks for 2024 here .

Are investors shorting Helius Medical Technologies?

Helius Medical Technologies saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 72,200 shares, a drop of 35.4% from the March 15th total of 111,800 shares. Based on an average daily trading volume, of 391,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 8.5% of the shares of the stock are short sold. View Helius Medical Technologies' Short Interest .

When is Helius Medical Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our HSDT earnings forecast .

How were Helius Medical Technologies' earnings last quarter?

Helius Medical Technologies, Inc. (NASDAQ:HSDT) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($3.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($5.50) by $2.50. The firm had revenue of $0.26 million for the quarter, compared to analysts' expectations of $0.17 million. Helius Medical Technologies had a negative net margin of 1,374.22% and a negative trailing twelve-month return on equity of 221.11%. During the same period in the previous year, the firm earned ($48.50) earnings per share.

When did Helius Medical Technologies' stock split?

Helius Medical Technologies's stock reverse split on Thursday, August 17th 2023. The 1-50 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Helius Medical Technologies?

Shares of HSDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:HSDT

Helius Medical Technologies (HSDT) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free HSDT Stock Alerts

$5.19

+0.08 (+1.57%)

(As of 10:03 AM ET)

Compare

Today's Range: $5.00
▼
$5.19
50-Day Range: $4.41
▼
$6.48
52-Week Range: $4.29
▼
$14.44

Volume: 2,816 shs
Average Volume: 336,499 shs
Market Capitalization: $4.62 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $54.50

Get Helius Medical Technologies alerts:

Helius Medical Technologies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 950.1% Upside
$54.50 Price Target
Short Interest: Healthy
8.53% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($7.42) to ($2.20) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.21 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Helius Medical Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Helius Medical Technologies has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
8.53% of the float of Helius Medical Technologies has been sold short.
Short Interest Ratio / Days to Cover
Helius Medical Technologies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Helius Medical Technologies has recently decreased by 35.42%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Helius Medical Technologies does not currently pay a dividend.
Dividend Growth
Helius Medical Technologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for HSDT.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Helius Medical Technologies this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Helius Medical Technologies to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Helius Medical Technologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.30% of the stock of Helius Medical Technologies is held by insiders.
Percentage Held by Institutions
Only 18.63% of the stock of Helius Medical Technologies is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Helius Medical Technologies are expected to grow in the coming year, from ($7.42) to ($2.20) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Helius Medical Technologies is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Helius Medical Technologies is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Helius Medical Technologies has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Helius Medical Technologies Stock (NASDAQ:HSDT)

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

HSDT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HSDT Stock News Headlines

April 17, 2024 | wsj.com

Helius Medical Technologies Inc.

April 15, 2024 | msn.com

Helius Medical files to sell Class A common stock, warrants

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 6, 2024 | msn.com

Helius Medical Technologies Partners with Lovell to Bring Innovative MS Treatment to Veterans

April 3, 2024 | msn.com

Why Is Nano-Cap Helius Medical Stock Trading Higher On Wednesday?

April 3, 2024 | seekingalpha.com

Helius Medical Technologies signs partnership with Lovell Government Services

April 3, 2024 | globenewswire.com

Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™

April 1, 2024 | finance.yahoo.com

Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q4 2023 Earnings Call Transcript

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 30, 2024 | seekingalpha.com

Helius Medical Technologies, Inc. (HSDT) Q4 2023 Earnings Call Transcript

March 29, 2024 | finance.yahoo.com

Q4 2023 Helius Medical Technologies Inc Earnings Call

March 28, 2024 | msn.com

Helius Medical Technologies GAAP EPS of -$1.47 beats by $2.30, revenue of $0.13M misses by $0.12M

March 28, 2024 | globenewswire.com

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

March 19, 2024 | msn.com

Helius Medical Technologies to Unveil Key Financial Results and U.S. Commercialization Plans for PoNS

March 15, 2024 | globenewswire.com

Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

March 12, 2024 | globenewswire.com

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

March 11, 2024 | msn.com

Helius Medical Technologies to Showcase Neurotech Innovations at the 36th Annual ROTH Conference

March 7, 2024 | globenewswire.com

Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference

March 4, 2024 | marketwatch.com

Helius Medical Shares Climb As PoNS Treatment Nears Reimbursement Milestone

March 4, 2024 | msn.com

Helius Medical stock rallies 19% on CMS code assignments

March 4, 2024 | msn.com

Why Is Neurotech-Focused Helius Medical Trading Higher On Monday?

March 4, 2024 | globenewswire.com

Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller

February 22, 2024 | investing.com

Helius Medical Technologies Inc Class A (HSDT)

February 7, 2024 | msn.com

Helius Medical Technologies Amplifies Presence at 2024 APTA Combined Sections Meeting

February 6, 2024 | msn.com

Traders Await Fresh Cues After Powell's Rate-Cut Commentary, Stifling US Equity Futures Pre-Bell

February 6, 2024 | msn.com

Helius Medical shares rally 25% on FDA meeting

February 6, 2024 | finance.yahoo.com

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

See More Headlines

Receive HSDT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Helius Medical Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/10/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Electromedical equipment
Sub-Industry: N/A
Current Symbol: NASDAQ:HSDT
CUSIP: N/A
CIK: 1610853
Web: heliusmedical.com
Phone: (877) 564-0008
Fax: N/A
Employees: 26
Year Founded: 2014

Price Target and Rating

Average Stock Price Target: $54.50
High Stock Price Target: $85.00
Low Stock Price Target: $24.00
Potential Upside/Downside: +950.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($14.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,850,000.00
Net Margins: -1,374.22%
Pretax Margin: -1,374.22%
Return on Equity: -221.11%
Return on Assets: -86.23%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.96
Quick Ratio: 3.72

Sales & Book Value

Annual Sales: $640,000.00
Price / Sales: 7.22
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.32 per share
Price / Book: 1.56

Miscellaneous

Outstanding Shares: 890,000
Free Float: 822,000
Market Cap: $4.62 million
Optionable: Not Optionable
Beta: 1.44

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Dane Carl Andreeff (Age 58)
President, CEO & Director
Comp: $469.17k
Dr. Antonella Favit-Van Pelt M.D. (Age 57)
Ph.D., Chief Medical Officer
Comp: $432.67k
Mr. Lawrence Picciano
Senior Vice President of Engineering, Quality & Regulatory Affairs

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

HSDT Stock Analysis - Frequently Asked Questions

Should I buy or sell Helius Medical Technologies stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HSDT shares.
View HSDT analyst ratings or view top-rated stocks.
What is Helius Medical Technologies' stock price target for 2024?: 1 brokerages have issued 12-month price targets for Helius Medical Technologies' stock. Their HSDT share price targets range from $24.00 to $85.00. On average, they anticipate the company's share price to reach $54.50 in the next year. This suggests a possible upside of 950.1% from the stock's current price.
View analysts price targets for HSDT or view top-rated stocks among Wall Street analysts.
How have HSDT shares performed in 2024?: Helius Medical Technologies' stock was trading at $8.04 at the beginning of the year. Since then, HSDT shares have decreased by 35.4% and is now trading at $5.19.
View the best growth stocks for 2024 here.
Are investors shorting Helius Medical Technologies?: Helius Medical Technologies saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 72,200 shares, a drop of 35.4% from the March 15th total of 111,800 shares. Based on an average daily trading volume, of 391,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 8.5% of the shares of the stock are short sold.
View Helius Medical Technologies' Short Interest.

When is Helius Medical Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HSDT earnings forecast.
How were Helius Medical Technologies' earnings last quarter?: Helius Medical Technologies, Inc. (NASDAQ:HSDT) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($3.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($5.50) by $2.50. The firm had revenue of $0.26 million for the quarter, compared to analysts' expectations of $0.17 million. Helius Medical Technologies had a negative net margin of 1,374.22% and a negative trailing twelve-month return on equity of 221.11%. During the same period in the previous year, the firm earned ($48.50) earnings per share.
When did Helius Medical Technologies' stock split?: Helius Medical Technologies's stock reverse split on Thursday, August 17th 2023. The 1-50 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
How do I buy shares of Helius Medical Technologies?: Shares of HSDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HSDT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Helius Medical Technologies (HSDT) Stock Price, News & Analysis

Helius Medical Technologies MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Helius Medical Technologies Stock (NASDAQ:HSDT)

HSDT Stock Price History

HSDT Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders

HSDT Stock Analysis - Frequently Asked Questions

Overall MarketRank^™